NCT01075321 - Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 13, 2020

Conditions

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaNodal Marginal Zone B-cell LymphomaPeripheral T-cell LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeSplenic Marginal Zone LymphomaWaldenstrom Macroglobulinemia

Interventions

DRUG

everolimus

Given orally

DRUG

lenalidomide

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

polymorphism analysis

Correlative studies

OTHER

immunohistochemistry staining method

Optional correlative studies

GENETIC

microarray analysis

Optional correlative studies

GENETIC

fluorescence in situ hybridization

Optional correlative studies

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale